Skip to main content
JUBILANT PHARMOVA LIMITED logo

JUBILANT PHARMOVA LIMITED — Investor Relations & Filings

Ticker · JUBLPHARMA ISIN · INE700A01033 LEI · 335800C6LDKWF4HQH833 BSE.NS Manufacturing
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2025-10-04 Regulatory Filings
Country IN India
Listing BSE.NS JUBLPHARMA

About JUBILANT PHARMOVA LIMITED

https://www.jubilantpharmova.com/

Jubilant Pharmova Limited is an integrated global pharmaceutical company operating through three primary segments: Pharmaceuticals, Contract Research and Development Services (CRDS), and Proprietary Novel Drugs. The Pharmaceuticals segment specializes in radiopharmaceuticals for nuclear medicine, allergy immunotherapy, and the development and manufacturing of generic formulations. It also provides Contract Development and Manufacturing Organization (CDMO) services for sterile injectables and non-sterile products. The CRDS division offers comprehensive drug discovery and development solutions to biopharmaceutical companies worldwide. Furthermore, the Proprietary Novel Drugs segment focuses on creating innovative therapies for oncology and autoimmune diseases. The company leverages its advanced manufacturing infrastructure and research capabilities to serve global markets with a focus on complex chemistry and specialized healthcare solutions.

Recent filings

Filing Released Lang Actions
General Updates
Regulatory Filings Classification · 95% confidence The document is a communication from Jubilant Pharmova Limited to shareholders regarding the transfer of unpaid/unclaimed dividends and equity shares to the Investor Education and Protection Fund (IEPF) Authority. It references regulatory provisions under the Companies Act, 2013 and SEBI Listing Obligations, and provides instructions for shareholders to claim dividends before transfer. The content is a reminder letter and notification to shareholders, not a financial report or detailed regulatory filing. It does not contain financial statements, audit information, or management discussion. The document is about shareholder communication concerning dividend claims and share transfers, which fits best under general regulatory announcements. It is not a report publication announcement since it is a substantive communication to shareholders about compliance and transfer of shares/dividends. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2025-10-04 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding the submission of copies of newspaper advertisements related to shareholder notices. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, which pertains to disclosure obligations. The content is about publishing notices to shareholders about investor education campaigns, re-lodgement of transfer requests, and KYC updates. The document is short (1683 characters) and does not contain any financial data, detailed reports, or management discussions. It is essentially an announcement of the publication of notices to shareholders rather than the notices themselves or any financial or governance report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-10-01 English
General Updates
Capital/Financing Update Classification · 95% confidence The document is a disclosure under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. It announces the allotment of Optionally Convertible Redeemable Non-Cumulative Preference Shares as part of consideration for acquiring a business segment. The content focuses on a capital transaction and financing activity related to share allotment and business acquisition. The document is short (1844 characters) and is an announcement rather than a detailed report or financial statement. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-10-01 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a short notice dated September 30, 2025, informing stock exchanges about the closure of the trading window for insiders ahead of the announcement of quarterly and half-year financial results. It does not contain any financial data or results itself, nor does it include detailed report content. The document serves as an announcement related to regulatory compliance and insider trading restrictions prior to financial results disclosure. Given its brief nature and purpose, it fits best as a Regulatory Filing (RNS) rather than a financial report or earnings release.
2025-09-30 English
Appointment
Board/Management Information Classification · 95% confidence The document is an official announcement from Jubilant Pharmova Limited regarding the appointment of a new Chief Financial Officer (CFO). It references compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content includes details about the appointment, effective date, interim period, and a brief profile of the appointee. There are no financial statements, earnings data, or detailed management discussion and analysis. The document is a formal disclosure of a management change, specifically the appointment of a senior executive (CFO). This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. The document length is under 5,000 characters and is not a report publication announcement or certification. Therefore, the appropriate classification is MANG with high confidence.
2025-09-23 English
Outcome of Board Meeting
Board/Management Information Classification · 95% confidence The document is an official announcement from Jubilant Pharmova Limited regarding the appointment of a new Chief Financial Officer (CFO). It references compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events including changes in key managerial personnel. The document includes details about the appointment, the effective date, and a brief profile of the appointee. There are no financial statements, earnings data, or detailed management discussion and analysis. The document is primarily about a change in senior management, specifically the CFO appointment, which fits the category of Board/Management Information (MANG). The document length is under 5,000 characters and is a direct announcement, not a report publication or certification. Therefore, the appropriate classification is MANG with high confidence.
2025-09-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.